Rossari Biotech Q2 FY27 Revenue Up 19% to ₹698 Crore; EBITDA Grows 21% to ₹87 Crore
Rossari Biotech reported Q2 FY27 revenue of ₹698 crore (up 19% YoY) and EBITDA of ₹87 crore (up 21% YoY). The company approved leasing land in Saudi Arabia for a new manufacturing facility. Exports contributed 31% of revenue, with plans to increase this further.
The announcement details strong financial performance in the current quarter, strategic expansion into a new international market (Saudi Arabia), and positive growth across key business segments, all of which are material to the company's future prospects.
The company reported strong year-on-year growth in revenue and EBITDA, achieved its highest-ever quarterly revenue and EBITDA, and made significant strategic progress with international expansion plans, indicating a positive financial and operational outlook.
Rossari Biotech Limited announced its financial results for the second quarter and first half of FY27, reporting a robust performance.
For Q2 FY27, the company's revenue from operations grew by 19% year-on-year to ₹697.6 crore, marking its highest-ever quarterly revenue. EBITDA also saw a significant increase of 21% year-on-year, reaching ₹87 crore, its highest quarterly EBITDA. The company achieved a gross margin of 31.6% and an EBITDA margin of 12.5% in Q2 FY27.
The growth was broad-based across all three business divisions: Home, Personal and Performance Chemicals (HPPC), Textile Specialty Chemicals, and Animal Health and Nutrition (AHN). HPPC revenue grew by 18% year-on-year to ₹541.9 crore, Textile Specialty Chemicals by 26% to ₹120.8 crore, and AHN by 11% to ₹34.8 crore.
The company highlighted its strategic initiatives, including the ramp-up of its new Rossari Global Research and Innovation Centre, a focus on sustainable chemistries, and expansion into international markets. A key development is the Board's approval for leasing land in Saudi Arabia for a new Greenfield manufacturing facility through its wholly-owned subsidiary, Rossari International Limited Company, aimed at enhancing access to raw materials and regional markets.
Management expressed confidence in delivering sustainable and profitable growth, supported by strong R&D, a healthy balance sheet, and disciplined execution. The company is also focusing on cost optimization, monetization of non-core assets, and improving operational efficiency to enhance margins.
What to do with a filing like this
Rossari Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rossari Biotech Limited. Read the original for the full detail.